In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

Ixekizumab reduces erosion and increases backfill in the sacroiliac joints of patients with radiographic axial ...

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has been added to ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

A terminally ill patient about to enter a hospice is in remission after AI found him a life-saving drug. Many people with serious illnesses, from cancer to heart failure, survive for years on ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, with a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo. The primary endpoint of the ...

EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...

Gene expression profiling could be a useful method for identifying markers predictive of response to tumor necrosis factor (TNF) blockade in patients with rheumatoid arthritis (RA), according to ...